A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Thyroid Eye Disease (TED)

In brief

This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).

Key facts

Study ID
NCT06812325
Run by
Viridian Therapeutics, Inc.
People needed
320
Starts
2025-02-03
Expected to finish
2026-10-01
Last updated by the study team
2026-05-22

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.